Medical hashish grower Glass Pharms has formally delivered its first crop to the UK's first clinic, marking the primary time because the legalization of medical hashish that domestically grown product has been made obtainable to sufferers.
The launch of medical hashish grown within the UK marks a big stage within the growth of the market, which has lengthy been hampered by its dependence on imported merchandise and its influence on provide chains.
One of many first clinics set to begin distributing the primary 'Made in Britain' printed medical hashish is Releaf, though Glass Pharms is known to be sending its product to various UK prospects.
“Our partnership with Glass Pharms represents a brand new period in medical hashish for the UK,” stated Tim Kirby, Managing Director of Releaf.
“By providing a domestically grown sustainable hashish remedy, we’re not solely responding to a big unmet want within the healthcare business and enhancing affected person entry, but additionally lowering our environmental influence and supporting the home business “.
Home provide
By way of its strategic partnership with Glass Pharms, Releaf now presents a variety of its personal branded medical hashish flower merchandise by way of its platform.
Glass Pharms has lengthy made its ambition to provide the home market clear, saying Hashish enterprise At first of this 12 months, the UK was its preliminary goal market, particularly “fixing issues out of inventory” for sufferers in the UK.
“We consider that if that offer chain is changed, and sufferers have the expertise of with the ability to obtain dependable, repeatable, standardized drugs that works, that removes one of many key items of friction from the business itself,” he stated.
To attain this, Glass Pharms says it has developed a “steady manufacturing mannequin”, which is able to harvest “each week of the 12 months”, considerably shortening the provision chain and permitting the corporate to offer recent flowers with “precise requirements” of terpene and cannabinoid. profiles.
Mr. Kirby stated Hashish Enterprise: “I didn't understand, after we launched into this journey in February, how damaged the provision chain was. These closed-loop ecosystems simply don't help any enterprise at scale.
“It was sort of this serendipitous second. We refunded £40,000 final month to sufferers as a result of we didn't meet our constitution by way of on-time supply. We stated we might ship in seven days, but it surely didn't occur.
“After which precisely the identical time I met James and Mark at Glass Pharms, and so they had an identical imaginative and prescient to me as to the reason for the UK stagnation, and so they had been actually about to have their first harvest.”
He continued that Releaf has agreed to purchase “as a lot of its early manufacturing as doable,” and has discovered a accomplice to deal with the shop, end and bundle Glass Pharms' product in Releaf-branded medical hashish flower.
“We've not solely secured the ecosystem by way of provide, however we've flattened the provision chain by way of the way it will get in entrance of the affected person.”
The pair stated they’ve agreed to a 12-month contract, which is able to see Glass Pharms use its steady progress cycle to successfully develop to Releaf's forecast “for 16 weeks out”.
The CEO of Glass Pharms, James Duckenfield, added: “Sufferers now have a safety of provide that was beforehand lacking from a market that beforehand relied on imports. The power for clinicians to jot down repeat prescriptions of the identical product was beforehand held as a result of provide chain points.Our steady harvesting mannequin will assist finish the out-of-stock points which have delayed the event of this promising therapeutic space within the UK.
Learn extra
Milestone for the UK as the primary medical hashish grown within the nation
